Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer.
breast conservation therapy
extreme oncoplasty
multicentric breast cancer
multifocal breast cancer
therapeutic mammoplasty
Journal
Breast cancer (Dove Medical Press)
ISSN: 1179-1314
Titre abrégé: Breast Cancer (Dove Med Press)
Pays: New Zealand
ID NLM: 101591856
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
02
2021
accepted:
22
04
2021
entrez:
3
6
2021
pubmed:
4
6
2021
medline:
4
6
2021
Statut:
epublish
Résumé
Extreme Oncoplastic Breast Conservation Surgery (EOBCS) is offered in selected patients with multifocal or multicentric breast cancer (MFMC). Recent evidence has suggested that EOBCS may be a valuable resource for patients with MFMC who may avoid the risk associated with mastectomy in favour of the benefits of breast conservation without risking their oncological outcomes. Our study examined the practice of EOBCS in two regional breast units in Glasgow, United Kingdom. A prospectively collected database of 50 patients treated with EOBC in two breast units in Glasgow between 2007 and 2018 were evaluated, and clinical outcomes were observed. Fifty patients (median age 55) underwent EOBCS, of which 43 (86%) had invasive disease. Median tumour size was 55mm (50-90) and multifocal disease was identified in 22 (44%) patients. Nine patients (18%) were found to have positive margins and underwent a second procedure, with 6 (12%) proceeding to mastectomy. Five-year disease free survival rate was 91.5%, while cancer-specific survival was 95.7%. EOBCS is oncologically safe in short-term follow-up. Large scale studies are required to confirm these preliminary results, in order to offer EOBCS as a valid option to patients with advanced or multifocal breast cancer.
Identifiants
pubmed: 34079367
doi: 10.2147/BCTT.S296242
pii: 296242
pmc: PMC8164874
doi:
Types de publication
Journal Article
Langues
eng
Pagination
353-359Informations de copyright
© 2021 Savioli et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Am J Surg. 2019 May;217(5):851-856
pubmed: 30771865
Gland Surg. 2013 Aug;2(3):143-57
pubmed: 25083476
Ann Surg Oncol. 2007 Feb;14(2):605-14
pubmed: 17151794
Eur J Surg Oncol. 2012 Mar;38(3):196-202
pubmed: 22206704
J Am Coll Surg. 2016 Jan;222(1):1-9
pubmed: 26778582
AJR Am J Roentgenol. 2004 Oct;183(4):1149-57
pubmed: 15385322
Breast J. 2019 May;25(3):535-536
pubmed: 30964211
Clin Radiol. 2005 May;60(5):573-8
pubmed: 15851045
Ann Surg Oncol. 2019 Feb;26(2):700-701
pubmed: 30414039
Breast. 2017 Apr;32:179-185
pubmed: 28214785
Eur J Surg Oncol. 2008 Oct;34(10):1143-7
pubmed: 17981430
Gland Surg. 2013 Aug;2(3):158-62
pubmed: 25083477
Eur J Surg Oncol. 2007 Aug;33 Suppl 1:S1-23
pubmed: 17604938
Breast Cancer (Dove Med Press). 2017 Aug 04;9:521-530
pubmed: 28831273
Breast J. 2015 Jan-Feb;21(1):52-9
pubmed: 25583035
Int J Breast Cancer. 2019 Feb 20;2019:4262589
pubmed: 30915240
Eur J Surg Oncol. 2018 Jul;44(7):939-944
pubmed: 29705287
J Clin Oncol. 2005 Oct 20;23(30):7497-502
pubmed: 16234516
Breast. 2015 Aug;24(4):497-501
pubmed: 26009307
Ann Surg. 2012 Jun;255(6):1151-7
pubmed: 22470069
Eur J Surg Oncol. 2020 Jan;46(1):71-76
pubmed: 31543385
Ann Surg Oncol. 2018 Oct;25(10):2858-2866
pubmed: 29987605
Br J Plast Surg. 2005 Oct;58(7):902-7
pubmed: 16043153
Ann Surg Oncol. 2016 Jun;23(6):1852-9
pubmed: 26842491
Eur J Cancer. 1990;26(6):668-70
pubmed: 2144152
Breast Cancer Res Treat. 2017 Aug;165(1):139-149
pubmed: 28578506
Eur J Surg Oncol. 2019 Oct;45(10):1806-1811
pubmed: 30902354
BJS Open. 2018 May 22;2(4):162-174
pubmed: 30079385
Breast. 2015 Apr;24(2):171-4
pubmed: 25623754
Ann R Coll Surg Engl. 2020 Jan;102(1):62-66
pubmed: 31891668
N Engl J Med. 2002 Oct 17;347(16):1227-32
pubmed: 12393819